Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 1-Year High – Still a Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) hit a new 52-week high during trading on Friday . The stock traded as high as $33.23 and last traded at $31.8550, with a volume of 240600 shares traded. The stock had previously closed at $30.75.

Analysts Set New Price Targets

Separately, UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the company has an average rating of “Strong Buy”.

Chugai Pharmaceutical Price Performance

The firm has a market cap of $105.67 billion, a PE ratio of 36.91 and a beta of 0.63. The firm has a 50-day simple moving average of $27.64 and a 200 day simple moving average of $25.03.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. The company had revenue of $2.25 billion during the quarter. Sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.